Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Curcumin  COVID-19 treatment studies for Curcumin  C19 studies: Curcumin  Curcumin   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent: 
0 0.5 1 1.5 2+ Viral clearance, day 10 53% Improvement Relative Risk Viral clearance, day 14 75% Viral clearance, day 21 67% c19curcumin.com Hartono et al. Curcumin for COVID-19 RCT LATE TREATMENT Favors curcumin Favors control
Hartono, 60 patient curcumin late treatment RCT: 53% improved viral clearance [p<0.0001] https://c19p.org/hartono
copied to clipboard
The Effect of Curcumin and Virgin Coconut Oil Towards Cytokines Levels in COVID-19 Patients at Universitas Sebelas Maret Hospital, Surakarta, Indonesia
Hartono et al., Pharmacognosy Journal, doi:10.5530/pj.2022.14.27
22 Feb 2022    Source   PDF   Share   Tweet
RCT with 30 patients treated with curcumin and virgin coconut oil (VCO), and 30 SOC patients in Indonesia, showing faster viral clearance with treatment. Treatment also reduced IL-1β, IL-2, IL-6, IL-18, and IFN-β levels. VCO improves the bioavailability of curcumin. There were large unadjusted differences in baseline severity and age, for example 20% vs. 47% of patients >50. VCO 30ml and curcumin 1g tid for 21 days. 066/UN27.06.6.1/KEPK/EC/2020.
risk of no viral clearance, 53.3% lower, RR 0.47, p < 0.001, treatment 14 of 30 (46.7%), control 30 of 30 (100.0%), NNT 1.9, day 10.
risk of no viral clearance, 75.0% lower, RR 0.25, p = 0.002, treatment 4 of 30 (13.3%), control 16 of 30 (53.3%), NNT 2.5, day 14.
risk of no viral clearance, 66.7% lower, RR 0.33, p = 1.00, treatment 0 of 30 (0.0%), control 1 of 30 (3.3%), NNT 30, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), day 21.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
This study is excluded in the after exclusion results of meta analysis: randomization resulted in significant baseline differences that were not adjusted for.
Hartono et al., 22 Feb 2022, Randomized Controlled Trial, Indonesia, peer-reviewed, 13 authors, this trial uses multiple treatments in the treatment arm (combined with virgin coconut oil) - results of individual treatments may vary.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperCurcuminAll
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit